Scarica l'app Stockscreener
824.06
0.69%
-5.70
Dopo l'orario di chiusura:
821.75
-2.31
-0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$829.76
Aprire:
$827.2
Volume 24 ore:
3.48M
Relative Volume:
1.04
Capitalizzazione di mercato:
$783.19B
Reddito:
$45.04B
Utile/perdita netta:
$10.59B
Rapporto P/E:
70.37
EPS:
11.71
Flusso di cassa netto:
$414.30M
1 W Prestazione:
-9.55%
1M Prestazione:
-4.73%
6M Prestazione:
-10.51%
1 anno Prestazione:
+12.21%
Intervallo 1D:
$811.64
$832.35
Intervallo di 1 settimana:
$811.64
$931.38
Portata 52W:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
824.06 | 783.19B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
213.59 | 377.06B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
78.11 | 346.73B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
165.86 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.73 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly Suit Over Compound Drugs Survives Dismissal - Law360
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes - STAT
Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025? - Insider Monkey
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss - AOL
Unpacking the Latest Options Trading Trends in Eli Lilly - Benzinga
Eli Lilly & Co: Promising CagriSema Performance Justifies Buy Rating Despite Tolerability Concerns - TipRanks
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock? - Nasdaq
Is Eli Lilly Stock a Buy? - The Motley Fool
Why Eli Lilly Stock Flopped Today - The Motley Fool
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. - Investor's Business Daily
Judge Denies Injunction for Copycats of Lilly's Weight Loss Drug - Bloomberg Law
Eli Lilly plans to launch weight-loss drug in emerging markets this year - Reuters.com
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study - Benzinga
Eli Lilly to debut weight loss drug in China, India - baha news
Morgan Stanley maintains Eli Lilly Overweight rating, $1,146 target By Investing.com - Investing.com South Africa
Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says - Bilyonaryo Business News
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says - Marketscreener.com
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus.com
Eli Lilly's Baricitinib Shows Promising Results for Adolescents with Severe Alopecia Areata - GuruFocus.com
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study - Investors | Eli Lilly and Company
Eli Lilly and Company (LLY): Jim Cramer Says ‘Don’t Sell’ – A Visionary Stock to Hold! - Insider Monkey
FDA Can Take Eli Lilly Weight Loss Drug Off Shortage List - Law360
Eli Lilly and Company (LLY): Among The Stocks With At Least $10 Million In Insider Sales Recently - Insider Monkey
Eli Lilly Says CEO David Ricks' 2024 Total Compensation Was $29.2 Million -March 07, 2025 at 04:10 pm EST - Marketscreener.com
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative - Indianapolis Business Journal
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugsWTAJ - WTAJ - www.wtaj.com
US judge denies injunction, restricting copies of Lilly weight-loss drug - Reuters
Eli Lilly and Company (LLY): Jim Cramer Sees a ‘Big Moat’ with Weight Loss Drug - Insider Monkey
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients - Benzinga
Eli Lilly posts long-term data for eczema therapy Ebglyss - Seeking Alpha
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan - Benzinga
Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis - Investors | Eli Lilly and Company
Consumers can buy Zepbound and Wegovy direct from drugmakers if they pay cash - WBEZ Chicago
Big Money Returning for Eli Lilly - FX Empire
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding - Benzinga
Two telehealth firms turn to branded Zepbound as restrictions loom on copies - Reuters
Third Time Lucky? Eli Lilly and Eisai Get Another Shot At English Funding For Alzheimer’s Drugs - Insights
Teladoc, LifeMD partner with Eli Lilly on GLP-1s - Modern Healthcare
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss - Benzinga
In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai - FiercePharma
Petri Dish: Biotech leaves Worcester; Novo Nordisk, Eli Lilly partnerships - The Business Journals
US judge denies injunction on Eli Lilly’s weight-loss drug copies - Investing.com
Here’s Why Eli Lilly and Company (LLY) has Come Under Pressure - Yahoo Finance
Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage - Seeking Alpha
Eli Lilly and Company (NYSE:LLY) Shares Bought by SOA Wealth Advisors LLC. - Defense World
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials - Benzinga
Wegovy Gets Cheaper! Novo Nordisk Takes on Eli Lilly as Obesity Drug Battle Heats Up - TipRanks
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly - Indianapolis Business Journal
Novo Nordisk goes direct to consumer with Wegovy. What it means for obesity rival Eli Lilly - CNBC
Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound - PBS NewsHour
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly - Colorado Hometown Weekly
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):